These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 20537530)

  • 41. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis.
    Moorman PG; Havrilesky LJ; Gierisch JM; Coeytaux RR; Lowery WJ; Peragallo Urrutia R; Dinan M; McBroom AJ; Hasselblad V; Sanders GD; Myers ER
    J Clin Oncol; 2013 Nov; 31(33):4188-98. PubMed ID: 24145348
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives.
    Runnebaum IB; Wang-Gohrke S; Vesprini D; Kreienberg R; Lynch H; Moslehi R; Ghadirian P; Weber B; Godwin AK; Risch H; Garber J; Lerman C; Olopade OI; Foulkes WD; Karlan B; Warner E; Rosen B; Rebbeck T; Tonin P; Dubé MP; Kieback DG; Narod SA
    Pharmacogenetics; 2001 Oct; 11(7):635-8. PubMed ID: 11668223
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reproductive factors and ovarian cancer risk in Jewish BRCA1 and BRCA2 mutation carriers (United States).
    Modugno F; Moslehi R; Ness RB; Nelson DB; Belle S; Kant JA; Wheeler JE; Wonderlick A; Fishman D; Karlan B; Risch H; Cramer DW; Dube MP; Narod SA
    Cancer Causes Control; 2003 Jun; 14(5):439-46. PubMed ID: 12946038
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers.
    Kotsopoulos J; Lubinski J; Moller P; Lynch HT; Singer CF; Eng C; Neuhausen SL; Karlan B; Kim-Sing C; Huzarski T; Gronwald J; McCuaig J; Senter L; Tung N; Ghadirian P; Eisen A; Gilchrist D; Blum JL; Zakalik D; Pal T; Sun P; Narod SA;
    Breast Cancer Res Treat; 2014 Feb; 143(3):579-86. PubMed ID: 24458845
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations.
    Milne RL; Knight JA; John EM; Dite GS; Balbuena R; Ziogas A; Andrulis IL; West DW; Li FP; Southey MC; Giles GG; McCredie MR; Hopper JL; Whittemore AS
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):350-6. PubMed ID: 15734957
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations.
    Whittemore AS; Balise RR; Pharoah PD; Dicioccio RA; Oakley-Girvan I; Ramus SJ; Daly M; Usinowicz MB; Garlinghouse-Jones K; Ponder BA; Buys S; Senie R; Andrulis I; John E; Hopper JL; Piver MS
    Br J Cancer; 2004 Nov; 91(11):1911-5. PubMed ID: 15545966
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group.
    Brohet RM; Goldgar DE; Easton DF; Antoniou AC; Andrieu N; Chang-Claude J; Peock S; Eeles RA; Cook M; Chu C; Noguès C; Lasset C; Berthet P; Meijers-Heijboer H; Gerdes AM; Olsson H; Caldes T; van Leeuwen FE; Rookus MA
    J Clin Oncol; 2007 Sep; 25(25):3831-6. PubMed ID: 17635951
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study.
    Figueiredo JC; Haile RW; Bernstein L; Malone KE; Largent J; Langholz B; Lynch CF; Bertelsen L; Capanu M; Concannon P; Borg A; Børresen-Dale AL; Diep A; Teraoka S; Torngren T; Xue S; Bernstein JL
    Breast Cancer Res Treat; 2010 Feb; 120(1):175-83. PubMed ID: 19597986
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pros and cons of screening for BRCA mutations.
    Howard-McNatt M
    N C Med J; 2013; 74(6):489-90. PubMed ID: 24316772
    [No Abstract]   [Full Text] [Related]  

  • 50. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers.
    Rebbeck TR
    Eur J Cancer; 2002 Nov; 38 Suppl 6():S15-7. PubMed ID: 12409058
    [No Abstract]   [Full Text] [Related]  

  • 51. Oral contraceptives and risk of breast cancer and ovarian cancer in women with a BRCA1 or BRCA2 mutation: a meta-analysis of observational studies.
    Park J; Huang D; Chang YJ; Lim MC; Myung SK
    Carcinogenesis; 2022 Apr; 43(3):231-242. PubMed ID: 34958358
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Explosive growth of uterine leiomyomas and carcinologic ovarian risk in a non-menopausal patient with BRCA1-BRCA2 mutation treated by tamoxifen].
    Doridot V; This P; Clough KB
    J Gynecol Obstet Biol Reprod (Paris); 2002 Nov; 31(7):677-80. PubMed ID: 12457141
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Skin cancer risk in BRCA1/2 mutation carriers.
    Gumaste PV; Penn LA; Cymerman RM; Kirchhoff T; Polsky D; McLellan B
    Br J Dermatol; 2015 Jun; 172(6):1498-1506. PubMed ID: 25524463
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Study clarifies risk of breast, ovarian cancer among mutation carriers.
    Reynolds T
    J Natl Cancer Inst; 2003 Dec; 95(24):1816-8. PubMed ID: 14679145
    [No Abstract]   [Full Text] [Related]  

  • 55. Variation in breast cancer risk in BRCA1 and BRCA2 mutation carriers.
    Rebbeck TR; Domchek SM
    Breast Cancer Res; 2008; 10(4):108. PubMed ID: 18710587
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Re: Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
    Hopper JL; Baron JA
    J Natl Cancer Inst; 2003 Jul; 95(13):1010-1; author reply 1012-3. PubMed ID: 12837841
    [No Abstract]   [Full Text] [Related]  

  • 57. Unravelling modifiers of breast and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: update on genetic modifiers.
    Barnes DR; Antoniou AC
    J Intern Med; 2012 Apr; 271(4):331-43. PubMed ID: 22443199
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers.
    Staton AD; Kurian AW; Cobb K; Mills MA; Ford JM
    Fam Cancer; 2008; 7(2):179-86. PubMed ID: 18026853
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Re: Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
    de Bock GH; Tollenaar RA; Papelard H; Vliet Vlieland TP; Devilee P; Cornelisse CJ; Vandenbroucke JP
    J Natl Cancer Inst; 2003 Jul; 95(13):1011-2; author reply 1012-3. PubMed ID: 12837842
    [No Abstract]   [Full Text] [Related]  

  • 60. BRCA1 and BRCA2 - update and implications on the genetics of breast cancer: a clinical perspective.
    Foulkes WD
    Clin Genet; 2014 Jan; 85(1):1-4. PubMed ID: 24116874
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.